Compare BioNTech SE - ADR (BNTX) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Expensify Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Expensify Inc trades at $1.81 (market cap $175.04M). The key difference: BioNTech SE - ADR is far larger — about 130.6× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | EXFY | |
|---|---|---|
Market Cap | $22.86B | $175.04M |
Sector | Health | Technology |
52-Week High | $119.34 | $2.33 |
52-Week Low | $83.89 | $0.75 |
Enterprise Value | $6.53B | $114.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Expensify (EXFY) trades at $1.79, down 5.29% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative net income margins. Recent news highlights product launches including AI-powered expense automation and a $25 million stock buyback program. Revenue remains stable around $140 million annually with improving cash flow from operations.
Outlook remains mixed with analyst consensus evenly split between Buy and Hold. Key opportunities include product innovation and cost management, while risks involve persistent profitability challenges and competitive pressure in expense management software. The stock's valuation shows high P/E ratio despite negative earnings, requiring careful fundamental assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
